Acrivon Therapeutics, Inc.
Nasdaq · CIK 0001781174 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-19.9M
Net Income
$-19.0M
Eps Basic
-0.49
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-19.9M | - | - |
| Net Income | $-19.0M | - | - |
| Eps Basic | -0.49 | - | - |
| Eps Diluted | -0.49 | - | - |
| Cash And Equivalents | $34.1M | - | - |
| Total Assets | $107.8M | - | - |
| Total Liabilities | $12.3M | - | - |
| Shareholders Equity | $95.5M | - | - |
| Operating Cash Flow | $-20.5M | - | - |
| Capital Expenditures | $14,000 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Acrivon Therapeutics, Inc. | 2026-05-13 | 0001193125-26-221634 |
| 10-K | Acrivon Therapeutics, Inc. | 2026-03-19 | 0001193125-26-115123 |
| 10-Q | Acrivon Therapeutics, Inc. | 2025-11-13 | 0001193125-25-280215 |
| 10-Q | Acrivon Therapeutics, Inc. | 2025-08-13 | 0000950170-25-108054 |